natgillin/translations-raw huggingface dataset:
The membrane separation device according to any one of claims 1 to 4, wherein the predetermined distance is set equal to or smaller than a half of the fixed distance. 
Uređaj za membransku separaciju (10) u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je unaprijed određena udaljenost (t) fiksirana na vrijednosti jednakoj ili manjoj od polovine fiksne udaljenosti (T).
Before secretory tests, the animals are deprived of food but not water for 20 h. 
Prije testa lučenja, životinje nisu dobivale hranu, ali su dobivale vodu tijekom 20 h.
The combination as defined in claim 10 wherein the lipid lowering agent is at least one agent selected from the group consisting of pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, nisvastatin, visastatin, atavastatin, rosuvastatin, fenofibrate, gemfibrozil, clofibrate and avasimibe. 
Kombinacija prema patentnom zahtjevu 10, naznačena time što je sredstvo za snižavanje nivoa lipida najmanje jedno sredstvo izabrano iz grupe koju čine pravastatin, lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, nisvastatin, visastatin, atavastatin, rosuvastatin, fenofibrat, gemfibrozil, klofibrat i avasimib.
and R2 together with the nitrogen atom to which they are attached form an azetidine, where the azetidine may have two substituents which, together with the carbon atom of the azetidine to which they are jointly attached, form an oxetane, represents hydrogen, and 
R' i R* zajedno s dušikovim atomom na koji su oni vezani tvore azetidin, gdje azetidin ima dva supstituenta koji, zajedno s ugljikovim atomom 1z azetidina na koji su zajednički vezani, tvore oksetan, R* predstavlja vodik,
The system of claim 5 wherein the first electrical source is also implanted; and wherein the controller component is operatively connected to the first electrical source by a wireless connection. 
Sustav sukladno zahtjevu 1 pri čemu je prvi električni izvor također usađen; i pri čemu je kontrolna komponenta operativno povezana s prvim električnim izvorom pomoću bežične veze.
Sample 250 mL of purified water from the reservoir in the dispensing area. 
Uzorak od 250 mL pročišćene vode iz rezervoara poslanje u laboratorij na testiranje na £.
The quantity of the prepared granulation is sufficient for the preparation of 10 units of 1 g tablets. 
Količina pripravljenog granulata dovoljna je za pripravu 10 jedinica tableta od lg dekstrometorfan 0,15 g tolperison
Therefore, according to a first aspect of the present invention there is provided a pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor, an amount of a HMG-CoA reductase inhibitor and at least one pharmaceutically acceptable auxiliary, wherein the PDE4 inhibitor is selected from the group consisting of ROFLUMILAST, a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable salt of ROFLUMILAST-N-oxide, the HMG-CoA reductase inhibitor is selected from ROSUVASTATIN or a pharmaceutically acceptable salt thereof, and wherein the first amount and the second amount together comprise an effective amount for the preventive or curative treatment of an inflammatory pulmonary disease. 
HR P20140707 T1 PATENTNI ZAHTJEVI Farmaceutski sastav, naznačen time, da obuhvaća farmaceutsku formulaciju koja uključuje jednu količinu PDE4- inhibitora, jednu količinu inhibitora reduktaze HMG-CoA i barem jedno farmaceutski prihvatljivo pomoćno sredstvo, dok je PDEA-inhibitor odabran iz skupine koja sadrži ROFLUMILAST, farmaceutski prihvatljivu sol ROFLUMILASTA, ROFLUMILAST-N-oksid i farmaceutski prihvatljivu sol ROFLUMILAST-N-oksida, gdje inhibitor reduktaze HMG-CoA je SIMVASTATIN ili njegova farmaceutski prihvatljiva sol, pri čemu prva količina i druga količina zajedno sastavljaju djelotvornu količinu za preventivno i kurativno liječenje upalne bolesti pluća.
A compound having the formula (1) or a stereochemically isomeric form thereof, wherein 
PATENTNI ZAHTJEVI L Spoj koji ima formulu (1)
A method for targeted integration of an artificial Immunoglobulin (Ig) locus in a recipient non-human germ cell, fertilised oocyte or embryo comprising: introducing into a recipient non-human germ cell, fertilised oocyte or embryo a site-specific meganuclease targeting an endogenous Ig locus and a transgenic vector comprising an artificial Ig locus such that the artificial Ig locus integrates into the genome of the recipient non-human germ cell, fertilised oocyte or embryo by targeted integration and replaces the endogenous Ig locus, or parts thereof, by homologous recombination; wherein the meganuclease increases the frequency of homologous recombination through double-strand DNA cleavage. 
HR P20180506 T1 PATENTNI ZAHTJEVI Postupak za ciljanu integraciju umjetnog imunoglobulinskog (ig) mjesta u primateliskoj ne-humanoj zametnoj stanici, oplođenoj jajnoj stanici ih embrijima, koji obuhvaća: uvođenje u ne-ljudsku zametnu stanicu primatelja, gnojivo jajne stanice ili embrij mjesto specifične meganukieaze usmjerene na endogeni ig lokus i transgenski vektor koji sadrži umjetni Ig lokus tako da umjetni Ig lokus integrira u genom primateljske ne-humane zametne stanice, oplođene oocite ih embrije ciljanom integracijom i zamjenjuje endogeni Ig lokus ili njihove dijelove homolognim rekombinacijom; gdje meganukleaza povećavaju učestalost homologne rekombinacije kroz dvostruko DNA cijepanje.
Another embodiment comprises a method for treating disease in a patient comprising administering thereto a composition comprising an ionizable drug, a crystallization inhibitor and a pH modifier, said composition providing a measurable improvement in dissolution rate of the ionizable drug. Another embodiment comprises a method for treating disease in a patient comprising administering thereto a composition comprising 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof, a crystallization inhibitor and a pH modifier, said composition providing a measurable improvement in dissolution rate of the ionizable drug. 
Uporaba 1-(6-amino-3,5-difluoropiridin-2-il)-8-klor-6-fluor-7-(3-hidroksiazetidin-1-11)-4-okso-1.4-dihidrokinolin-3-karboksilne kiseline ili njezine soli, inhibitora kristalizacije izabranog iz skupine koja obuhvaća hidroksipropilmetilcelulozu, polivinilpirolidon i hidroksipropilcelulozu te modifikatora pH za proizvodnju smjese, naznačena time, da ima mjerljivo poboljšan stupanj otapanja 1-(6-amino-3,5-difluoropiridin-2-11)-8-klor-6-fluor-7- (3-hidroksiazetidin-1-il)-4-okso-1.4-dihidrokinolin-3-karboksilne kiseline ili njezine soli za liječenje bolesti kod bolesnika kojemu će se dati ta smjesa.
determining (62) a likelihood of modifying the parsed field that does not match the valid characteristic of the valid corresponding field to generate a valid field based upon, at least in part, one or more empirically determined rules, wherein the empirically determined rules are based upon, at least in part, possible errors that occur in the parsed field and the possible modifications that may be implemented to correct each possible error. 
prebacivanju u ispravljenu prijenosnu izvršnu datoteku jedne ili više tablica adresa unosa, na osnovi, u najmanju ruku djelomično, prikupljenih podataka iz tablica adresa unosa, i tablica premiještanja, na osnovi, u najmanju ruku djelomično, prikupljenih podataka iz tablica premiještanja; kopiranju ispravljene prijenosne izvršne datoteke u memoriji na memorijski medij; i prekidanju postupka uklanjanja pogrešaka.
The pharmaceutical composition for use of claim 14 wherein said inflammation of the gastrointestinal tract comprises inflammation of the esaphagus, eosinophilic esophagius, inflammation of the glottis, epiglottis, tonsils or oropharynx, gastroesophageal reflux disease (GERD), nanoerosive reflux disease (NERD), erosive esophagitis, or inflammation caused by bacteria or virus. 
ODT za uporabu sukladno zahtjevu 14, naznačena time, što navedena upalno stanje gastrointestinalnog trakta obuhvaća upalu jednjaka, eozinofilni ezofagitis, ili upalu ždrijela, epiglotisa, krajnika ili orofarinksa.
A method of receiving a broadcasting signal, the method suitable for: 
Postupak primanja emitiranog signala, postupak obuhvaća:
These toolstrings are lowered or driven into the wellbores, and include various devices that are activatable within the wellbores at the downhole location to carry out predetermined tasks. 
Ovi alati se spuštaju ili umeću u bušotinu i sadrže različite uređaje koji se mogu aktivirati unutar bušotine na određenom mjestu u bušotini da bi izvršili unaprijed određene zadatke.
Device according to one of the preceding claims, in which the columns (12, 13) are arranged in a regular pattern around in each case a passage (11). 
Sustav za prihvat tekućina u skladu s patentnim zahtjevom 3, naznačen time što otvori na bočnim stijenkama (11-13) su poravnani s vodoravno položenim kanalom (6-8).
wet grinding said suspension; 
(b) vlažnog mljevenja navedene suspenzije;
Preferably a two- to tenfold excess of the alkali metal nitrite is used, more preferably a four- to sixfold excess. Suitable crown ethers can be readily chosen by those skilled in the art, mainly depending on what alkali metal nitrite is applied, and include 18-crown-6-ether, 15-crown-5-ether. 
Postupak u skladu s bilo kojim patentnim zahtjevom od 1 do 3, naznačen time što krunasti eter je 18-kruna-6-eter u slučaju upotrebe kalijevog nitrita, a 15-kruna-5-eter u slučaju upotrebe natrijevog nitrita.
the gaming server upon, receiving the user-presence-signal, is adapted to request a credit value of the user terminal and the value of the e-wallet; and wherein if the credit value is zero and the e-wallet value is greater than zero, then a disable-signal is sent to the biometric data server and/or biometric device. 
Postupak sukladno patentnom zahtjevu 10, pri čemu posla zahteva za obje, i vrijednosti kredita korisničkog terminala (2), i vrijednosti računa e-novčanika (71), ukoliko je račun e-novčanika nula, tada se, ukoliko je vrijednost kredita korisničkog terminala (2) veća od nule, prijenosi vrijednost kredita s korisničkog terminala (2) na račun e-novčanika 71.
The disclosure also comprises a kit for the prediction of the chance of a successful pregnancy, comprising: 
Komplet za predviđanje vjerojatnosti za uspješnu trudnoću, naznačen time da sadrži: a.
HIV integrase inhibitors have been reported to prevent viral integration and inhibited HIV-1 replication in cells (Hazuda et al. 
Za inhibitore HIV integraze objavljeno je da sprečavaju ugradnju virusa i inhibiraju replikaciju HIV-1 u stanicama (Hazuda ct al.
A compound of Formula I: and N-oxides, pharmaceutically acceptable salts, solvates, and stereochemical isomers thereof, wherein: 
Spoj s formulom I: [image] i N-oksidi, farmaceutski prihvatljive soli, solvati, te njihovi stereokemijski izomeri, naznačen time da:
Meldonium and the corresponding acid are dissolved in a small quantity of water at 40–50° C. under stirring. 
Meldonij i odgovarajuća kiselina se otope u maloj količini vode pri 40-50*%C uz miješanje.
associated with gastronintestinal ulceration, wherein optionally the gastrointestinal ulceration is associated with infectious colitis, ischemic colitis, collagenous or lymphocytic colitis or necrotizing enterocolitis. 
reumatoidni artritis; ili vi) povezano sa gastrointestinalnom ulceracijom, pri čemu je gastrointestinalna ulceracija opcionalno povezana sa zaraznim kolitisom, iskemijskim kolitisom, kolagenim ili limfocitnim kolitisom ili nekrotizirajućim enterokolitisom;
purifying the carbamylated erythropoietin protein using anion exchange, cation exchange, hydrophobic interaction chromatography, reverse phase chromatography, affinity chromatography or size exclusion chromatography. 
(b) pročišćavanje karbamiliranog proteina eritropoetina primjenom anionske izmjene, kationske izmjene, kromatografije zasnovane na hidrofobnim interakcijama, reverzno fazne kromatografije, afinitetne kromatografije ili ekskluzione kromatografije.
The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is to be administered intradermally, in particular by tattooing, microneedling and/or microneedle patches. 
Farmaceutski sastav prema patentnom zahtjevu 4, gdje se farmaceutski sastav primjenjuje intradermalno tetoviranjem, mikroiglom i/ili flasterima sa mikroiglama.
The wound dressing as claimed in claim 1 characterised in that the longitudinal lines of stitching are from 1 mm to 10 mm apart and are parallel to a long edge of the strip. 
Povoj za rane prema zahtjevu 1 naznačen time što su uzdužni štepovi razmaknuti od 1 mm do 10 mm i što su paralelni dužem rubu trake.
providing at least one candidate sequence which consists of an amino acid sequence modified by substituting one or two amino acid residues to an original amino acid sequence, wherein the original amino acid sequence is selected from the group consisting of SEQ ID NOs: 100, 80, and 101; 
osiguravanja najmanje jednog slijeda kandidata koji se sastoji od aminokiselinskog slijeda modificiranog zamjenom 1 ili dva aminokiselinska ostatka u izvornom aminokiselinskom slijedu, gdje se izvorni aminokiselinski slijed bira iz skupine koju čine SEQ ID NO: 194, 174, 178 i 186;
The metal substrate of any one of claims 10 to 14, wherein the metal substrate is a coin blank or a negotiable coin. 
Metalna podloga u skladu s patentnim zahtjevom 9, naznačena time što je metalna podloga prenosiva kovanica.
Use according to claim 13, wherein said malignant cells are cells from a tumor selected in the group consisting of a haematological tumor and a solid tumor. 
Uporaba ili nanočestice HfO, ili agregati nanočestica HfO> za uporabu prema zahtjevu 13, gdje su spomenute maligne stanice stanice od tumora odabranog iz skupine koju čine hematološki tumor i solidni tumor.
A transdermal delivery device comprising: a polymer matrix layer comprising an opioid agonist with intermixed microspheres comprising opioid antagonist, wherein the opioid antagonist is non-releasable when the transdermal delivery device is applied topically and intact, and wherein the microspheres are in a mean size of from 1 to 300 µm in diameter. 
Sredstvo za transdermalno davanje koje sadrži: sloj koji sadrži lijek gdje navedeni sloj sadrži učinkovitu količinu opioidnog agonista i veći broj mikrosfera dispergiranih u sloju koji sadrži lijek, mikrosfere koje sadrže opioidni antagonist i gdje su mikrosfere srednje veličine od 1 do 300 um u promjeru.
placing concrete forms, having a cavity, where the wall is to be constructed; placing a limited quantity of metal reinforcement within the cavity, such that the limited quantity of metal reinforcement is insufficient to meet the applicable building code; and pouring a mix of aggregate, sand, cement, fly ash, and mineral fibers into the cavity, wherein the mix contains approximately 48.24% stone, 33.15% sand, 10.32% Portland cement, 6.88% fly ash, 1.41 % mineral fibers of different grades comprising calcium inosilicate (CaSiO3) fibers or mineral fibers of different grades comprising one or more minerals of the pyroxene group of minerals, and less than 0.005% of admixtures by weight, 
Postupak prema zahtjevu 1, naznačen time što je struktura zid, postupak obuhvaća korake: postavljanje betonskih kalupa, koji imaju šupljine, na mjesto gdje se zid postavlja; postavljanje ograničene količine metalnih pojačanja unutar šupljina, tako da ograničena količina metalnih pojačanja nije dovoljna da ispuni uvjete primjenjivih građevinskih propisa; i lijevanje smjese agregata, pijeska, cementa, letećeg pepela i mineralnih vlakana u šupljine, gdje smjesa sadrži oko 48,24% kamena, 33,15% pijeska, 10,32% Portland cementa, 6,88% letećeg pepela, 1,41% mineralnih vlakana različitih klasa koja sadrže kalcijeva inosilikatna (CaSiO:) vlakna 1li mineralna vlakna različitih klasa koja sadrže jedan ili više minerala iz piroksenske skupine minerala i manje od 0,005% mješavina po težini; ostavljanje smjese da se stvrdne u kalupima, pri čemu se ispunjavanju uvjeti primjenjivih građevinskih propisa bez dodatnih metalnih pojačanja.
R is hydrogen or tritium; 
R je vodik ili tricij;
A process for producing a detergent-free preparation of bacterial outer membrane vesicles (OMV) for use in vaccines, said process comprising the steps of: cultivating a population of Gram-negative bacteria in culture to stationary growth phase; beginning at a time at least about 1 hour after onset of the stationary growth phase, incubating the bacteria obtained in step (a) in a medium adjusted to, or having a pH higher than, pH 8.0 and a concentration of a metal chelating agent of between about 1 and 100 mM to extract said bacterial OMV; and 
Postupak za pripremu bez deterdženta bakterijskih vezikula vanjske membrane (OMV) za uporabu u cjepivima, navedeni postupak obuhvaća korake: a) kultivacije populacije Gram-negativne bakterije do stacionarne faze rasta; b) u vremenskom trenutku najmanje 1 sat nakon početka stacionarne faze rasta, inkubacije bakterija dobivenih u a) u mediju koji je podešen na, ili ima pH vrijednost višu od pH 8.0 i koncentraciju metal-kelatnog sredstva, poželjno EDTA, između 1 i 100 mM, za ekstrakciju OMV; i, c) ponovnog dobivanja OMV ekstrahiranih u b), pri čemu ponovno dobivanje obuhvaća najmanje uklanjanje bakterija iz OMV.
The compound of claim 1 or 2, wherein R2 is CH3 and/or wherein X6 is C-H or. wherein X6 is N. 
Spoj u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da R2 je CH3 i/ili pri čemu X6 je C-H ili u kojem X6 je N.
measuring the oxygen content of exhaust gas from the catalyst using an oxygen sensor, and using this information to modulate air input to the catalyst or to the chamber or to both the catalyst and the chamber so as to maintain the oxygen level of gas exiting the apparatus; and 
- - mjerenje sadržaja kisika u ispušnom plinu iz katalizatora pomoću osjetnika kisika i korištenje tih podataka za moduliranje dovoda zraka u katalizator ili u komoru ili i u katalizator i u komoru, kako bi se održavala razina kisika u plinu koji izlazi iz uređaja; i
A product produced by a process comprising: 
Produkt dobiven postupkom koji sadrži:
The security member may be shaped such that the packaging must be opened in order to access the security member. 
Zaštitni član može biti oblikovan tako da se pakiranje mora otvoriti da bi se pristupilo zaštitnom članu.
The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition further comprises a glidant constituting from 0.1 to 0.5% by weight of the pharmaceutical composition. 
Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-5, gdje sol klorovodične kiseline spoja 1 je u čvrstom kristalnom obliku.
No. 37 a N- oxide form, an addition salt or a stereochemically isomeric form thereof. 
OH Spoj br. 37 njihovog N-oksidnog oblika, adicijske soli ili stereokemijskog izomernog oblika.
‘a’ is an integer from 1 to about 6. 
'a'je cijeli broj 1 do 6.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. 
Farmaceutski oblici pogodni za injekcije uključuju sterilne vodene otopine ili disperzije i sterilne praške za ekstemporalnu pripravu sterilnih injekcijskih otopina ili disperzija.
The method of claim 2, wherein the solid form exhibits a weight loss of about 0.16% of the total sample weight upon heating from about 25 to about 120° C. 
Čvrsti oblik prema zahtjevu 1, naznačen time što pokazuje gubitak težine od oko 0.16% ukupne mase uzorka nakon grijanja od oko 25 do oko 120 "€.
It was used directly. 
Korišten je direktno.
The device 1 comprises a pair of suction cups 3, 4 fastened to the support structure 2 and active on a first external lateral face of a flexible container, preferably in correspondence with an inlet thereof. 
Uređaj 1 sadržava jedan par usisnih čašica 3, 4 koje su pričvršćene na nosivu konstrukciju 2 1 koje djeluje na prvu vanjsku bočnu plohu savitljivog spremnika, za koju plohu je poželjno da je povezana s njegovim ulaznim otvorom.
In another aspect the present invention provides the compound of the invention for use in the treatment, prevention or prophylaxis of an inflammatory condition. 
Spoj za uporabu prema zahtjevu 6, naznačen time da upalno stanje je upalna bolest crijeva.
Use of nanoparticles or nanoparticles' aggregates for the preparation of a pharmaceutical composition for use in a method of altering or destroying target cells in an animal when said cells are exposed to ionizing radiations, wherein each nanoparticle or nanoparticles' aggregate consists of a metal oxide selected from the group consisting of CeO2, Tm2O3, HfO2, WO3 and PdO, wherein the density of said nanoparticle or the density of said nanoparticles' aggregate is of at least 7,1 g/cm3 when the metal oxide is CeO2, of at least 8,3 g/cm3 when the metal oxide is Tm2O3, of at least 7,4 g/cm3 when the metal oxide is HfO2, of at least 7,2 g/cm3 when the metal oxide is WO3, and of at least 7,9 g/cm3 when the metal oxide is PdO, and wherein each nanoparticle or nanoparticles' aggregate is covered with a biocompatible coating allowing the nanoparticle or nanoparticles' aggregate stability between pH 6.5 and 7.5 in a physiological fluid. 
HR P20181993 T1 PATENTNI ZAHTJEVI Uporaba nanočestica HfO, ili agregata nanočestica HfO, za pripremu farmaceutskog pripravka za uporabu u postupku mijenjanja ili uništavanja ciljnih stanica u životinje kada su spomenute stanice izložene ionizirajućim zračenjima, pri čemu je gustoća spomenutih nanočestica HfO, ili gustoća spomenutih agregata nanočestica HfO, barem 7 g/cm', i pri čemu je svaka nanočestica ili agregat nanočestica obložen biokompatibilnom ovojnicom koja daje nanočestici ili agregatu nanočestica stabilnost između pH 6,5 1 7,5 u fiziološkoj tekućini.
A composition for use according to Claim 1 or a composition as claimed in Claim 8. wherein the weight ratio of the cyclodextrin to 4-iodo-3-nitro-benzamide is from 1:100 to 5000: 1. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili pripravak u skladu s patentnim zahtjevom 8, naznačen time što je težinski omjer između ciklodekstrina i 4-jod-3-nitrobenzamida od 1:100 do 5000:1.
187 30 Vaccine comprising at least two fragments of Proprotein convertase subtilisin/kexin type 9 (PCSK9), wherein at least one fragment of said at least two fragments comprises at least 8 consecutive amino acid residues of amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID No. 9). 
Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 153 do 165 od PCSK9 u skladu sa SEQ ID NO:9,1 gdje barem jedan od navedena najmanje dva fragmenta sadrži najmanje devet uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 209 do 222 od PCSK9 u skladu sa SEQ ID NO:9.
A nucleic acid molecule encoding the conjugate of claim 7 . A vector or a set of vectors comprising the nucleic acid molecule of claim 12 . 
Vektor ili set vektora koji sadrži molekulu nukleinske kiseline ili set molekula nukleinske kiseline prema zahtjevu 8 ili njihov komplement.
An antibody molecule composition obtainable by a production method comprising the steps of 
Pripravak s molekulom protutijela, naznačen time što se može načiniti postupkom proizvodnje koji se sastoji u koracima
grinding, heating, co-subliming, co-melting, or contacting in solution VX-950 with the co-crystal former under crystallization condition so as to form the co-crystal in solid phase, and optionally isolating the co-crystal formed by step (c), or 
ČHa s 4-hidroksibenzojevom kiselinom u uvjetima kristaliziranja, tako da nastane sukristal u čvrstoj fazi, i d) izborno izdvajanju sukristala nastalog u koraku (c). 18.